The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS‐CoV‐2 variant
The main coronavirus disease 2019 (COVID‐19) vaccine formulations used today are mainly based on the wild‐type severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike glycoprotein as an antigen. However, new virus variants capable of escaping neutralization activity of serum antibodies el...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2023-02, Vol.95 (2), p.e28481-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 2 |
| container_start_page | e28481 |
| container_title | Journal of medical virology |
| container_volume | 95 |
| creator | Farias, Jéssica P. Pinheiro, Josilene R. Andreata‐Santos, Robert Fogaça, Mayanna M. C. Silva Brito, Ruth D. Cruz, Edgar F. Castro‐Amarante, Maria F. Pereira, Samuel S. Santos Almeida, Shirley Moreira, Ludimila M. Conceição Simões, Rafael Luiz, Wilson B. Birbrair, Alexander Belmok, Aline Ribeiro, Bergmann M. Maricato, Juliana T. Braconi, Carla T. Souza Ferreira, Luís C. Janini, Luiz M. R. Amorim, Jaime Henrique |
| description | The main coronavirus disease 2019 (COVID‐19) vaccine formulations used today are mainly based on the wild‐type severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike glycoprotein as an antigen. However, new virus variants capable of escaping neutralization activity of serum antibodies elicited in vaccinated individuals have emerged. The Omicron (B.1.1.529) variant caused epidemics in regions of the world in which most of the population has been vaccinated. In this study, we aimed to understand what determines individual's susceptibility to Omicron in a scenario of extensive vaccination. For that purpose, we collected nasopharynx swab (n = 286) and blood samples (n = 239) from flu‐like symptomatic patients, as well as their vaccination history against COVID‐19. We computed the data regarding vaccine history, COVID‐19 diagnosis, COVID‐19 serology, and viral genome sequencing to evaluate their impact on the number of infections. As main results, we showed that vaccination in general did not reduce the number of individuals infected by Omicron, even with an increased immune response found among vaccinated, noninfected individuals. Nonetheless, we found that individuals who received the third vaccine dose showed significantly reduced susceptibility to Omicron infections. A relevant evidence that support this finding was the higher virus neutralization capacity of serum samples of most patients who received the third vaccine dose. In summary, this study shows that boosting immune responses after a third vaccine dose reduces susceptibility to COVID‐19 caused by the Omicron variant. Results presented in this study are useful for future formulations of COVID‐19 vaccination policies. |
| doi_str_mv | 10.1002/jmv.28481 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2761986067</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2761986067</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-30fc37437e358e8a7a73a12c2ba6f217be21871891de9a8d416550b03e37b9783</originalsourceid><addsrcrecordid>eNp1kctO3DAUhq0KVAbaRV-gssQGFhl87MSXJR31hkBIhbKNHOekeJTLYCdUs-MR-ow8CYaBLpCQJXvz-dN_zk_IJ2BzYIwfLbvbOde5hndkBszIzDAFW2TGIJeZlFDskN0Yl4wxbTh_T3aElAnTcka6y2uk47UPNb21zvkeaT1EpNH_6X3jne3Hdk0D1pPDSOMUHa5GX_nWj2s6Dukr0i9zSKfghh6cd96FoT-kF8e_Lu7v_i2Gq3Tz5A4-qT6Q7ca2ET8-v3vk97evl4sf2en595-L49PMCa0hE6xxQuVCoSg0aqusEha445WVDQdVIQetQBuo0Vhd5yCLglVMoFCVUVrskYONdxWGmwnjWHY-JW9b2-MwxZIrCUZLJlVC91-hy2EKfUqXKGVyzguARB1uqDRdjAGbchV8Z8O6BFY-dlCmDsqnDhL7-dk4VR3W_8mXpSfgaAP89S2u3zaVJ2dXG-UDxaCPXg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2779422511</pqid></control><display><type>article</type><title>The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS‐CoV‐2 variant</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Farias, Jéssica P. ; Pinheiro, Josilene R. ; Andreata‐Santos, Robert ; Fogaça, Mayanna M. C. ; Silva Brito, Ruth D. ; Cruz, Edgar F. ; Castro‐Amarante, Maria F. ; Pereira, Samuel S. ; Santos Almeida, Shirley ; Moreira, Ludimila M. ; Conceição Simões, Rafael ; Luiz, Wilson B. ; Birbrair, Alexander ; Belmok, Aline ; Ribeiro, Bergmann M. ; Maricato, Juliana T. ; Braconi, Carla T. ; Souza Ferreira, Luís C. ; Janini, Luiz M. R. ; Amorim, Jaime Henrique</creator><creatorcontrib>Farias, Jéssica P. ; Pinheiro, Josilene R. ; Andreata‐Santos, Robert ; Fogaça, Mayanna M. C. ; Silva Brito, Ruth D. ; Cruz, Edgar F. ; Castro‐Amarante, Maria F. ; Pereira, Samuel S. ; Santos Almeida, Shirley ; Moreira, Ludimila M. ; Conceição Simões, Rafael ; Luiz, Wilson B. ; Birbrair, Alexander ; Belmok, Aline ; Ribeiro, Bergmann M. ; Maricato, Juliana T. ; Braconi, Carla T. ; Souza Ferreira, Luís C. ; Janini, Luiz M. R. ; Amorim, Jaime Henrique</creatorcontrib><description>The main coronavirus disease 2019 (COVID‐19) vaccine formulations used today are mainly based on the wild‐type severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike glycoprotein as an antigen. However, new virus variants capable of escaping neutralization activity of serum antibodies elicited in vaccinated individuals have emerged. The Omicron (B.1.1.529) variant caused epidemics in regions of the world in which most of the population has been vaccinated. In this study, we aimed to understand what determines individual's susceptibility to Omicron in a scenario of extensive vaccination. For that purpose, we collected nasopharynx swab (n = 286) and blood samples (n = 239) from flu‐like symptomatic patients, as well as their vaccination history against COVID‐19. We computed the data regarding vaccine history, COVID‐19 diagnosis, COVID‐19 serology, and viral genome sequencing to evaluate their impact on the number of infections. As main results, we showed that vaccination in general did not reduce the number of individuals infected by Omicron, even with an increased immune response found among vaccinated, noninfected individuals. Nonetheless, we found that individuals who received the third vaccine dose showed significantly reduced susceptibility to Omicron infections. A relevant evidence that support this finding was the higher virus neutralization capacity of serum samples of most patients who received the third vaccine dose. In summary, this study shows that boosting immune responses after a third vaccine dose reduces susceptibility to COVID‐19 caused by the Omicron variant. Results presented in this study are useful for future formulations of COVID‐19 vaccination policies.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.28481</identifier><identifier>PMID: 36609686</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Antibodies ; Antibodies, Neutralizing ; Antibodies, Viral ; antibody ; Antigens ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 Testing ; COVID-19 vaccines ; COVID-19 Vaccines - administration & dosage ; COVID-19 Vaccines - immunology ; Epidemics ; Gene sequencing ; Genomes ; Glycoproteins ; Humans ; Immune response ; Immune system ; Infections ; Nasopharynx ; Neutralization ; Public health ; SARS-CoV-2 ; Serology ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Spike glycoprotein ; Spike Glycoprotein, Coronavirus ; Susceptibility ; vaccination policy ; vaccine doses ; Vaccines ; Viral diseases ; Virology ; Viruses</subject><ispartof>Journal of medical virology, 2023-02, Vol.95 (2), p.e28481-n/a</ispartof><rights>2023 The Authors. y published by Wiley Periodicals LLC.</rights><rights>2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-30fc37437e358e8a7a73a12c2ba6f217be21871891de9a8d416550b03e37b9783</citedby><cites>FETCH-LOGICAL-c3881-30fc37437e358e8a7a73a12c2ba6f217be21871891de9a8d416550b03e37b9783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.28481$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.28481$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36609686$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Farias, Jéssica P.</creatorcontrib><creatorcontrib>Pinheiro, Josilene R.</creatorcontrib><creatorcontrib>Andreata‐Santos, Robert</creatorcontrib><creatorcontrib>Fogaça, Mayanna M. C.</creatorcontrib><creatorcontrib>Silva Brito, Ruth D.</creatorcontrib><creatorcontrib>Cruz, Edgar F.</creatorcontrib><creatorcontrib>Castro‐Amarante, Maria F.</creatorcontrib><creatorcontrib>Pereira, Samuel S.</creatorcontrib><creatorcontrib>Santos Almeida, Shirley</creatorcontrib><creatorcontrib>Moreira, Ludimila M.</creatorcontrib><creatorcontrib>Conceição Simões, Rafael</creatorcontrib><creatorcontrib>Luiz, Wilson B.</creatorcontrib><creatorcontrib>Birbrair, Alexander</creatorcontrib><creatorcontrib>Belmok, Aline</creatorcontrib><creatorcontrib>Ribeiro, Bergmann M.</creatorcontrib><creatorcontrib>Maricato, Juliana T.</creatorcontrib><creatorcontrib>Braconi, Carla T.</creatorcontrib><creatorcontrib>Souza Ferreira, Luís C.</creatorcontrib><creatorcontrib>Janini, Luiz M. R.</creatorcontrib><creatorcontrib>Amorim, Jaime Henrique</creatorcontrib><title>The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS‐CoV‐2 variant</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>The main coronavirus disease 2019 (COVID‐19) vaccine formulations used today are mainly based on the wild‐type severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike glycoprotein as an antigen. However, new virus variants capable of escaping neutralization activity of serum antibodies elicited in vaccinated individuals have emerged. The Omicron (B.1.1.529) variant caused epidemics in regions of the world in which most of the population has been vaccinated. In this study, we aimed to understand what determines individual's susceptibility to Omicron in a scenario of extensive vaccination. For that purpose, we collected nasopharynx swab (n = 286) and blood samples (n = 239) from flu‐like symptomatic patients, as well as their vaccination history against COVID‐19. We computed the data regarding vaccine history, COVID‐19 diagnosis, COVID‐19 serology, and viral genome sequencing to evaluate their impact on the number of infections. As main results, we showed that vaccination in general did not reduce the number of individuals infected by Omicron, even with an increased immune response found among vaccinated, noninfected individuals. Nonetheless, we found that individuals who received the third vaccine dose showed significantly reduced susceptibility to Omicron infections. A relevant evidence that support this finding was the higher virus neutralization capacity of serum samples of most patients who received the third vaccine dose. In summary, this study shows that boosting immune responses after a third vaccine dose reduces susceptibility to COVID‐19 caused by the Omicron variant. Results presented in this study are useful for future formulations of COVID‐19 vaccination policies.</description><subject>Antibodies</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>antibody</subject><subject>Antigens</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Testing</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - administration & dosage</subject><subject>COVID-19 Vaccines - immunology</subject><subject>Epidemics</subject><subject>Gene sequencing</subject><subject>Genomes</subject><subject>Glycoproteins</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Infections</subject><subject>Nasopharynx</subject><subject>Neutralization</subject><subject>Public health</subject><subject>SARS-CoV-2</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike glycoprotein</subject><subject>Spike Glycoprotein, Coronavirus</subject><subject>Susceptibility</subject><subject>vaccination policy</subject><subject>vaccine doses</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Virology</subject><subject>Viruses</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctO3DAUhq0KVAbaRV-gssQGFhl87MSXJR31hkBIhbKNHOekeJTLYCdUs-MR-ow8CYaBLpCQJXvz-dN_zk_IJ2BzYIwfLbvbOde5hndkBszIzDAFW2TGIJeZlFDskN0Yl4wxbTh_T3aElAnTcka6y2uk47UPNb21zvkeaT1EpNH_6X3jne3Hdk0D1pPDSOMUHa5GX_nWj2s6Dukr0i9zSKfghh6cd96FoT-kF8e_Lu7v_i2Gq3Tz5A4-qT6Q7ca2ET8-v3vk97evl4sf2en595-L49PMCa0hE6xxQuVCoSg0aqusEha445WVDQdVIQetQBuo0Vhd5yCLglVMoFCVUVrskYONdxWGmwnjWHY-JW9b2-MwxZIrCUZLJlVC91-hy2EKfUqXKGVyzguARB1uqDRdjAGbchV8Z8O6BFY-dlCmDsqnDhL7-dk4VR3W_8mXpSfgaAP89S2u3zaVJ2dXG-UDxaCPXg</recordid><startdate>202302</startdate><enddate>202302</enddate><creator>Farias, Jéssica P.</creator><creator>Pinheiro, Josilene R.</creator><creator>Andreata‐Santos, Robert</creator><creator>Fogaça, Mayanna M. C.</creator><creator>Silva Brito, Ruth D.</creator><creator>Cruz, Edgar F.</creator><creator>Castro‐Amarante, Maria F.</creator><creator>Pereira, Samuel S.</creator><creator>Santos Almeida, Shirley</creator><creator>Moreira, Ludimila M.</creator><creator>Conceição Simões, Rafael</creator><creator>Luiz, Wilson B.</creator><creator>Birbrair, Alexander</creator><creator>Belmok, Aline</creator><creator>Ribeiro, Bergmann M.</creator><creator>Maricato, Juliana T.</creator><creator>Braconi, Carla T.</creator><creator>Souza Ferreira, Luís C.</creator><creator>Janini, Luiz M. R.</creator><creator>Amorim, Jaime Henrique</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>202302</creationdate><title>The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS‐CoV‐2 variant</title><author>Farias, Jéssica P. ; Pinheiro, Josilene R. ; Andreata‐Santos, Robert ; Fogaça, Mayanna M. C. ; Silva Brito, Ruth D. ; Cruz, Edgar F. ; Castro‐Amarante, Maria F. ; Pereira, Samuel S. ; Santos Almeida, Shirley ; Moreira, Ludimila M. ; Conceição Simões, Rafael ; Luiz, Wilson B. ; Birbrair, Alexander ; Belmok, Aline ; Ribeiro, Bergmann M. ; Maricato, Juliana T. ; Braconi, Carla T. ; Souza Ferreira, Luís C. ; Janini, Luiz M. R. ; Amorim, Jaime Henrique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-30fc37437e358e8a7a73a12c2ba6f217be21871891de9a8d416550b03e37b9783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>antibody</topic><topic>Antigens</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Testing</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - administration & dosage</topic><topic>COVID-19 Vaccines - immunology</topic><topic>Epidemics</topic><topic>Gene sequencing</topic><topic>Genomes</topic><topic>Glycoproteins</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Infections</topic><topic>Nasopharynx</topic><topic>Neutralization</topic><topic>Public health</topic><topic>SARS-CoV-2</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike glycoprotein</topic><topic>Spike Glycoprotein, Coronavirus</topic><topic>Susceptibility</topic><topic>vaccination policy</topic><topic>vaccine doses</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farias, Jéssica P.</creatorcontrib><creatorcontrib>Pinheiro, Josilene R.</creatorcontrib><creatorcontrib>Andreata‐Santos, Robert</creatorcontrib><creatorcontrib>Fogaça, Mayanna M. C.</creatorcontrib><creatorcontrib>Silva Brito, Ruth D.</creatorcontrib><creatorcontrib>Cruz, Edgar F.</creatorcontrib><creatorcontrib>Castro‐Amarante, Maria F.</creatorcontrib><creatorcontrib>Pereira, Samuel S.</creatorcontrib><creatorcontrib>Santos Almeida, Shirley</creatorcontrib><creatorcontrib>Moreira, Ludimila M.</creatorcontrib><creatorcontrib>Conceição Simões, Rafael</creatorcontrib><creatorcontrib>Luiz, Wilson B.</creatorcontrib><creatorcontrib>Birbrair, Alexander</creatorcontrib><creatorcontrib>Belmok, Aline</creatorcontrib><creatorcontrib>Ribeiro, Bergmann M.</creatorcontrib><creatorcontrib>Maricato, Juliana T.</creatorcontrib><creatorcontrib>Braconi, Carla T.</creatorcontrib><creatorcontrib>Souza Ferreira, Luís C.</creatorcontrib><creatorcontrib>Janini, Luiz M. R.</creatorcontrib><creatorcontrib>Amorim, Jaime Henrique</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farias, Jéssica P.</au><au>Pinheiro, Josilene R.</au><au>Andreata‐Santos, Robert</au><au>Fogaça, Mayanna M. C.</au><au>Silva Brito, Ruth D.</au><au>Cruz, Edgar F.</au><au>Castro‐Amarante, Maria F.</au><au>Pereira, Samuel S.</au><au>Santos Almeida, Shirley</au><au>Moreira, Ludimila M.</au><au>Conceição Simões, Rafael</au><au>Luiz, Wilson B.</au><au>Birbrair, Alexander</au><au>Belmok, Aline</au><au>Ribeiro, Bergmann M.</au><au>Maricato, Juliana T.</au><au>Braconi, Carla T.</au><au>Souza Ferreira, Luís C.</au><au>Janini, Luiz M. R.</au><au>Amorim, Jaime Henrique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS‐CoV‐2 variant</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2023-02</date><risdate>2023</risdate><volume>95</volume><issue>2</issue><spage>e28481</spage><epage>n/a</epage><pages>e28481-n/a</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>The main coronavirus disease 2019 (COVID‐19) vaccine formulations used today are mainly based on the wild‐type severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike glycoprotein as an antigen. However, new virus variants capable of escaping neutralization activity of serum antibodies elicited in vaccinated individuals have emerged. The Omicron (B.1.1.529) variant caused epidemics in regions of the world in which most of the population has been vaccinated. In this study, we aimed to understand what determines individual's susceptibility to Omicron in a scenario of extensive vaccination. For that purpose, we collected nasopharynx swab (n = 286) and blood samples (n = 239) from flu‐like symptomatic patients, as well as their vaccination history against COVID‐19. We computed the data regarding vaccine history, COVID‐19 diagnosis, COVID‐19 serology, and viral genome sequencing to evaluate their impact on the number of infections. As main results, we showed that vaccination in general did not reduce the number of individuals infected by Omicron, even with an increased immune response found among vaccinated, noninfected individuals. Nonetheless, we found that individuals who received the third vaccine dose showed significantly reduced susceptibility to Omicron infections. A relevant evidence that support this finding was the higher virus neutralization capacity of serum samples of most patients who received the third vaccine dose. In summary, this study shows that boosting immune responses after a third vaccine dose reduces susceptibility to COVID‐19 caused by the Omicron variant. Results presented in this study are useful for future formulations of COVID‐19 vaccination policies.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36609686</pmid><doi>10.1002/jmv.28481</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2023-02, Vol.95 (2), p.e28481-n/a |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2761986067 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antibodies Antibodies, Neutralizing Antibodies, Viral antibody Antigens Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Testing COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Epidemics Gene sequencing Genomes Glycoproteins Humans Immune response Immune system Infections Nasopharynx Neutralization Public health SARS-CoV-2 Serology Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Spike Glycoprotein, Coronavirus Susceptibility vaccination policy vaccine doses Vaccines Viral diseases Virology Viruses |
| title | The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS‐CoV‐2 variant |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A21%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20third%20vaccine%20dose%20significantly%20reduces%20susceptibility%20to%20the%20B.1.1.529%20(Omicron)%20SARS%E2%80%90CoV%E2%80%902%20variant&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Farias,%20J%C3%A9ssica%20P.&rft.date=2023-02&rft.volume=95&rft.issue=2&rft.spage=e28481&rft.epage=n/a&rft.pages=e28481-n/a&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.28481&rft_dat=%3Cproquest_cross%3E2761986067%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2779422511&rft_id=info:pmid/36609686&rfr_iscdi=true |